| Literature DB >> 9625439 |
A Vasuratna1, A P Kudelka, C L Edwards, V Wootipoom, C F Verschraegen, C Charnsangavej, J J Kavanagh.
Abstract
Recurrent endometrial cancer has grave prognosis. Chemotherapy and hormonal therapy are mainstays of palliative treatment. Unfortunately the frequency of complete response and duration of progression-free interval are limited. This case report describes a patient with recurrent metastatic endometrial cancer who was initially treated with radiotherapy followed by surgery. Her recurrent tumor progressed during treatment with external radiation and a progestogen. She received paclitaxel (135 mg/m2 i.v. infusion over 24 h) and carboplatin (AUC 7.5 microg x h/ml) every 4 weeks with complete remission after 8 months which has persisted for 22 months. Paclitaxel and carboplatin combination should be considered for the treatment of endometrial cancer.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9625439 DOI: 10.1097/00001813-199803000-00011
Source DB: PubMed Journal: Anticancer Drugs ISSN: 0959-4973 Impact factor: 2.248